Stay updated with breaking news from Reiterates Neutral. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BMO Capital's Kelly Bania reiterates Market Perform for Target but lowers the price target from $170 to $155. Despite 1Q results meeting expectations, concerns arise over continued gross margin upside, share losses in food and consumables, and competition from Amazon and Walmart.
Goldman Sachs maintains a Neutral rating on KO with a $60.00 price target. Analyst Bonnie Herzog highlights KO's robust Q1 organic revenue growth of 11%, exceeding expectations. Despite this, limited EPS growth potential might weigh on the stock in the near term, notes the analyst. Truist and BofA Securities analysts reiterate Buy rating.
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.